Drug that helps MS patients walk faster approved in US
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The US Food and Drug Administration (FDA) has approved a drug which has been found to allow with multiple sclerosis (MS) to walk faster, the drug watchdog said.
Multiple sclerosis patients treated with the drug, Ampyra - generic name dalfampridine - were found in clinical trials to have faster walking speeds than those treated with a placebo, the FDA said.
"Trouble with walking is one of the most debilitating problems people with MS face," Russell Katz, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement Saturday.
Ampyra is the first drug approved by the FDA to help improve MS patients' walking.
Multiple sclerosis is a chronic, often disabling disease that affects the brain, spinal cord and optic nerves.
Around 2.5 million people worldwide, including 400,000 in the United States, have MS, according to Multiple Sclerosis Society.
kdz/mk
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments